BRIEF — Chinese biotech targets $414 million in Hong Kong IPO

The latest Chinese biotech attempting a listing on the Hong Kong exchange is not holding back in its ambitions.

Shanghai Junshi Biosciences, which has 13 biologics in development, hopes to raise $414 million in its bid to go public, reports Reuters.

Chinese biotechs have been pursuing Hong Kong listings since new regulations were introduced in April that allow them to do so even if they have no revenue or profit.